Middle Meningeal Artery Embolization: A Breakthrough Treatment for Chronic Subdural Hematomas
Chronic subdural hematomas (cSDH) are a growing health concern, particularly in older adults and those taking blood thinners. These brain bleeds, which occur between the brain’s surface and its outer covering (the dura), can develop slowly over weeks or months and often recur after traditional surgery.
Now, a minimally invasive procedure called Middle Meningeal Artery Embolization (MMAE) is changing how doctors treat this condition—offering long-term relief with less risk, no need for open brain surgery, and faster recovery times.
What Is a Chronic Subdural Hematoma?
A subdural hematoma is a collection of blood between the surface of the brain and the dura mater, its outermost protective layer. A chronic subdural hematoma typically results from minor head trauma, especially in elderly patients whose brain tissue has shrunk with age or who are on blood-thinning medications.
Over time, this blood can collect and cause pressure on the brain, leading to symptoms such as:
- Headaches
- Memory loss or confusion
- Balance problems or falls
- Slurred speech
- Muscle weakness
- Seizures
Traditional Treatment: Surgery Has Limits
Standard treatment for cSDH often involves bur hole drainage or craniotomy—invasive surgical techniques that relieve pressure by removing blood. While these methods can be effective, they come with risks such as infection, recurrence, and the need for prolonged hospitalization.
Unfortunately, recurrence is common—up to 30% of patients may experience a re-accumulation of blood requiring additional surgeries. That’s where Middle Meningeal Artery Embolization comes in.
What Is Middle Meningeal Artery Embolization?
MMAE is an outpatient, catheter-based procedure performed by an interventional radiologist. It targets the middle meningeal artery—a key blood vessel supplying the dura and the outer membrane that fuels the cycle of bleeding and inflammation behind chronic subdural hematomas.
Using real-time imaging (fluoroscopy), a catheter is inserted into a blood vessel in the wrist or groin and guided to the artery. Once there, tiny particles are injected to block blood flow, cutting off the source of recurrent bleeding and allowing the hematoma to resolve naturally over time.
How MMAE Works
The success of MMAE lies in addressing the root cause of cSDH: fragile capillaries within the dura that continue to leak blood. By embolizing (blocking) the middle meningeal artery, the procedure reduces inflammation, halts further bleeding, and helps the body reabsorb the accumulated blood.
Benefits of MMAE
- Minimally invasive—no brain incision
- Lower risk of recurrence compared to surgery
- Performed under light sedation or local anesthesia
- Often done as an outpatient or 23-hour observation
- Shorter recovery time
- Can be used alone or after initial drainage surgery
Who Is a Candidate for MMAE?
- Patients with confirmed chronic subdural hematomas
- Those at high risk for surgical complications
- Patients with recurrence after surgical drainage
- Individuals on blood thinners
- Patients seeking non-surgical alternatives
What to Expect During the Procedure
After mild sedation and local anesthesia, a small catheter is inserted into a blood vessel in the groin or wrist and guided to the middle meningeal artery. Embolic particles are then injected to block blood flow to the affected area. The procedure typically takes 60–90 minutes.
Post-Procedure and Recovery
Most patients return home the same day or after one night of observation. Mild headaches or fatigue may occur but resolve quickly. Follow-up imaging is used to monitor resolution of the hematoma.
Clinical Evidence and Effectiveness
Studies show MMAE significantly reduces recurrence, improves outcomes, and in many cases, prevents the need for surgical drainage altogether. Recurrence rates are as low as 5–10% when compared to 20–30% with surgery alone.
MMAE vs. Surgical Drainage
| Feature | MMAE | Surgery |
|---|---|---|
| Invasiveness | Minimally invasive | Highly invasive |
| Recurrence Risk | 5–10% | 20–30% |
| Anesthesia | Local + sedation | General anesthesia |
| Recovery | 2–3 days | 1–2 weeks |
Why Choose FKMD?
At FKMD, we offer state-of-the-art, image-guided procedures like MMAE to treat conditions traditionally requiring invasive surgery. Our expert interventional radiologists deliver compassionate, customized care that prioritizes safety, outcomes, and your quality of life.
Call to Learn More
If you or a loved one has a chronic subdural hematoma, Middle Meningeal Artery Embolization may be a safer, more effective treatment option.
📞 Call us today at 650-404-8445 to schedule a consultation.
